BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Staphylococcus aureus M0987 |
👶
Luteolin attenuates Staphylococcus aureus-induced endometritis through inhibiting ferroptosis and inflammation via activating the Nrf2/GPX4 signaling pathway. Microbiology spectrum (Microbiol Spectr ) Vol: 12 Issue 2 Pages: e0327923 Pub: 2024 Feb 6 Epub: 2024 Jan 3 Authors Gao S , Gao Y , Cai L , Qin R , Html Article Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Staphylococcus aureus M0987 |
👶
Pithecellobium clypearia extract enriched in gallic acid and luteolin has antibacterial activity against MRSA and reduces resistance to erythromycin, ceftriaxone sodium and levofloxacin. Journal of applied microbiology (J Appl Microbiol ) Vol: 129 Issue 4 Pages: 848-859 Pub: 2020 Oct Epub: 2020 May 3 Authors Liu C , Huang H , Zhou Q , Liu B , Wang Y , Li P , Liao K , Su W , Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Staphylococcus aureus M0987 |
👶
The Mechanism by Which Luteolin Disrupts the Cytoplasmic Membrane of Methicillin-Resistant Staphylococcus aureus. The journal of physical chemistry. B (J Phys Chem B ) Vol: 122 Issue 4 Pages: 1427-1438 Pub: 2018 Feb 1 Epub: 2018 Jan 23 Authors Zhang T , Qiu Y , Luo Q , Zhao L , Yan X , Ding Q , Jiang H , Yang H , Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Staphylococcus aureus M0987 |
👶
Synthesis and biological evaluation of novel luteolin derivatives as antibacterial agents. European journal of medicinal chemistry (Eur J Med Chem ) Vol: 44 Issue 2 Pages: 908-14 Pub: 2009 Feb Epub: 2008 Jan 25 Authors Lv PC , Li HQ , Xue JY , Shi L , Zhu HL , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
